Paul Kelly compensation by year
RELMADA THERAPEUTICS Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $499,800 |
| Bonus | $1,085,480 |
| Stock awards | $0 |
| Option awards | $3,328,819 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $375,000 |
| Total | $5,289,099 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RELMADA THERAPEUTICS, INC. DEF 14A filed April 17, 2026, accession 0001213900-26-045192, and prior-year filings. Open the filing on EDGAR.
How this page was built: the RELMADA THERAPEUTICS, INC. filed document, accession 0001213900-26-045192. Every figure is read from that document and cited to the page and table it appears in. Filed April 17, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 37,500 | — | $3.37 |
| Option | 32,836 | — | $2.48 |
| Option | 350,000 | — | $0.67 |
| Option | 828,000 | — | $4.06 |
Per the Outstanding Equity Awards at Fiscal Year-End table in RELMADA THERAPEUTICS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
RELMADA THERAPEUTICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sergio Traversa | Chief Executive Officer | $8,892,633 |
| Maged Shenouda | Chief Financial Officer | $6,091,453 |
| Charles Ence | Chief Accounting and Compliance Officer | $5,497,026 |
| Paul Kelly · this page | Chief Operating Officer | $5,289,099 |
Board service
RELMADA THERAPEUTICS board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $70,620 | $0 | $0 | $802,160 | $872,780 |
| FY2024 | $66,000 | $0 | $140,275 | $534,000 | $740,275 |
| FY2023 | $66,000 | $0 | $1,068,019 | $534,000 | $1,668,019 |
| FY2021 | $83,500 | $0 | — | $0 | — |
Each year as the company reported it in RELMADA THERAPEUTICS's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: RELMADA THERAPEUTICS pays directors a $74,152 cash retainer. As stated in RELMADA THERAPEUTICS's FY2025 proxy.
Paul Kelly's compensation dossier, RELMADA THERAPEUTICS
You have read Paul Kelly's totals and holdings. The dossier adds each equity grant RELMADA THERAPEUTICS disclosed for Paul Kelly and RELMADA THERAPEUTICS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full RELMADA THERAPEUTICS compensation record
free company briefThis page is one person within RELMADA THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the RELMADA THERAPEUTICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order RELMADA THERAPEUTICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RELMADA THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order RLMD
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.